Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Zura Bio LtdZURA · Entity 5413 | Director | June 17, 2026 | June 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Zura Bio Ltd
Report date June 17, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.62 · Expires 2036-06-17 | Direct | 51,000 |
Reported balance
After 2026-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 51,000 · Balance 51,000 F1: This option vests in twelve substantially equal monthly installments over a one-year period measured from June 17, 2026; provided, that any remaining unvested portion of the option award will vest as of the day immediately preceding the next annual meeting of shareholders following the grant date, subject to the Reporting Person's continued service as of each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests in twelve substantially equal monthly installments over a one-year period measured from June 17, 2026; provided, that any remaining unvested portion of the option award will vest as of the day immediately preceding the next annual meeting of shareholders following the grant date, subject to the Reporting Person's continued service as of each such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Tourmaline Bio, Inc.
Report date October 28, 2025 · Filed October 28, 2025
Section 16 reporting ended · disclosed 2025-10-28. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-10-28 transaction · row 1
1 source rowRow 1 · 2025-10-28 · Other · Disposed 83,782 · Balance 0 F1: This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 8, 2025, by and among Issuer, Novartis AG, a company limited by shares (Aktiengesellschaft) incorporated under the laws of Switzerland ("Parent"), and Torino Merger Sub Inc., a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on October 28, 2025, Merger Sub completed a cash tender offer to acquire all of the shares of common stock of the Issuer, par value $0.0001 (the "Shares"), issued and outstanding immediately prior to the effective time of the merger (the "Effective Time"), in exchange for $48.00 in cash per Share, subject to any applicable withholding of taxes (the "Merger Consideration"). F2: Pursuant to the terms of the Merger Agreement, each Share was tendered in exchange for $48.00 in cash per Share. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.46 | Direct | 0 |
Reported balance
After 2025-10-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-10-28 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 8, 2025, by and among Issuer, Novartis AG, a company limited by shares (Aktiengesellschaft) incorporated under the laws of Switzerland ("Parent"), and Torino Merger Sub Inc., a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on October 28, 2025, Merger Sub completed a cash tender offer to acquire all of the shares of common stock of the Issuer, par value $0.0001 (the "Shares"), issued and outstanding immediately prior to the effective time of the merger (the "Effective Time"), in exchange for $48.00 in cash per Share, subject to any applicable withholding of taxes (the "Merger Consideration"). F3: Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.91 | Direct | 0 |
Reported balance
After 2025-10-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-10-28 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 8, 2025, by and among Issuer, Novartis AG, a company limited by shares (Aktiengesellschaft) incorporated under the laws of Switzerland ("Parent"), and Torino Merger Sub Inc., a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on October 28, 2025, Merger Sub completed a cash tender offer to acquire all of the shares of common stock of the Issuer, par value $0.0001 (the "Shares"), issued and outstanding immediately prior to the effective time of the merger (the "Effective Time"), in exchange for $48.00 in cash per Share, subject to any applicable withholding of taxes (the "Merger Consideration"). F3: Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.73 | Direct | 0 |
Reported balance
After 2025-10-28 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-10-28 · Disposition to issuer · Disposed 16,800 · Balance 0 F1: This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 8, 2025, by and among Issuer, Novartis AG, a company limited by shares (Aktiengesellschaft) incorporated under the laws of Switzerland ("Parent"), and Torino Merger Sub Inc., a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on October 28, 2025, Merger Sub completed a cash tender offer to acquire all of the shares of common stock of the Issuer, par value $0.0001 (the "Shares"), issued and outstanding immediately prior to the effective time of the merger (the "Effective Time"), in exchange for $48.00 in cash per Share, subject to any applicable withholding of taxes (the "Merger Consideration"). F3: Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 8, 2025, by and among Issuer, Novartis AG, a company limited by shares (Aktiengesellschaft) incorporated under the laws of Switzerland ("Parent"), and Torino Merger Sub Inc., a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on October 28, 2025, Merger Sub completed a cash tender offer to acquire all of the shares of common stock of the Issuer, par value $0.0001 (the "Shares"), issued and outstanding immediately prior to the effective time of the merger (the "Effective Time"), in exchange for $48.00 in cash per Share, subject to any applicable withholding of taxes (the "Merger Consideration").
F2: Pursuant to the terms of the Merger Agreement, each Share was tendered in exchange for $48.00 in cash per Share.
F3: Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 17, 2026 Filed Jun 22, 2026 20:15 UTC | Zura Bio Ltd ZURA · Entity 5413 | GrantShare Option (Right to Buy) · Derivative | 51,000 | $0.00 Strike: $3.62 | $0.00 |
DisclosureSEC source: 0001995535-26-000008 · form4-06222026_040610.xml · derivative · entry 1 Thiara Parvinder · CIK 0001995535 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,000 Underlying: Class A Ordinary Shares · 51,000 shares Expires 2036-06-17 F1 · derivative.exercise_date: This option vests in twelve substantially equal monthly installments over a one-year period measured from June 17, 2026; provided, that any remaining unvested portion of the option award will vest as of the day immediately preceding the next annual meeting of shareholders following the grant date, subject to the Reporting Person's continued service as of each such vesting date. Read SEC document |
| January 23, 2026 Filed Jan 27, 2026 23:45 UTC | Zura Bio Ltd ZURA · Entity 5413 | GrantShare Option (Right to Buy) · Derivative | 38,823 | $0.00 Strike: $6.36 | $0.00 |
DisclosureSEC source: 0001995535-26-000006 · form4-01272026_110130.xml · derivative · entry 1 Thiara Parvinder · CIK 0001995535 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,823 Underlying: Class A Ordinary Shares · 38,823 shares Expires 2036-01-23 F1 · derivative.exercise_date: This option vests in twelve substantially equal monthly installments over a one-year period measured from January 23, 2026; provided, that any remaining unvested portion of the option award will vest as of the day immediately preceding the next annual meeting of shareholders following the grant date, subject to the Reporting Person's continued service as of each such vesting date. Read SEC document |
| October 28, 2025 Filed Oct 28, 2025 18:30 UTC | Tourmaline Bio, Inc. TRML · Entity 15643 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 16,800 | Not disclosed Strike: $18.73 | Not disclosed |
DisclosureSEC source: 0001995535-25-000003 · form4-10282025_061019.xml · derivative · entry 4 Thiara Parvinder · CIK 0001995535 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,800 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 8, 2025, by and among Issuer, Novartis AG, a company limited by shares (Aktiengesellschaft) incorporated under the laws of Switzerland ("Parent"), and Torino Merger Sub Inc., a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on October 28, 2025, Merger Sub completed a cash tender offer to acquire all of the shares of common stock of the Issuer, par value $0.0001 (the "Shares"), issued and outstanding immediately prior to the effective time of the merger (the "Effective Time"), in exchange for $48.00 in cash per Share, subject to any applicable withholding of taxes (the "Merger Consideration"). F3 · price: Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes. F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes. Read SEC document |
| October 28, 2025 Filed Oct 28, 2025 18:30 UTC | Tourmaline Bio, Inc. TRML · Entity 15643 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 10,000 | Not disclosed Strike: $13.91 | Not disclosed |
DisclosureSEC source: 0001995535-25-000003 · form4-10282025_061019.xml · derivative · entry 3 Thiara Parvinder · CIK 0001995535 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 8, 2025, by and among Issuer, Novartis AG, a company limited by shares (Aktiengesellschaft) incorporated under the laws of Switzerland ("Parent"), and Torino Merger Sub Inc., a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on October 28, 2025, Merger Sub completed a cash tender offer to acquire all of the shares of common stock of the Issuer, par value $0.0001 (the "Shares"), issued and outstanding immediately prior to the effective time of the merger (the "Effective Time"), in exchange for $48.00 in cash per Share, subject to any applicable withholding of taxes (the "Merger Consideration"). F3 · price: Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes. F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes. Read SEC document |
| October 28, 2025 Filed Oct 28, 2025 18:30 UTC | Tourmaline Bio, Inc. TRML · Entity 15643 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 10,000 | Not disclosed Strike: $9.46 | Not disclosed |
DisclosureSEC source: 0001995535-25-000003 · form4-10282025_061019.xml · derivative · entry 2 Thiara Parvinder · CIK 0001995535 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 8, 2025, by and among Issuer, Novartis AG, a company limited by shares (Aktiengesellschaft) incorporated under the laws of Switzerland ("Parent"), and Torino Merger Sub Inc., a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on October 28, 2025, Merger Sub completed a cash tender offer to acquire all of the shares of common stock of the Issuer, par value $0.0001 (the "Shares"), issued and outstanding immediately prior to the effective time of the merger (the "Effective Time"), in exchange for $48.00 in cash per Share, subject to any applicable withholding of taxes (the "Merger Consideration"). F3 · price: Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes. F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes. Read SEC document |
| October 28, 2025 Filed Oct 28, 2025 18:30 UTC | Tourmaline Bio, Inc. TRML · Entity 15643 | OtherCommon Stock | 83,782 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001995535-25-000003 · form4-10282025_061019.xml · nonDerivative · entry 1 Thiara Parvinder · CIK 0001995535 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 8, 2025, by and among Issuer, Novartis AG, a company limited by shares (Aktiengesellschaft) incorporated under the laws of Switzerland ("Parent"), and Torino Merger Sub Inc., a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on October 28, 2025, Merger Sub completed a cash tender offer to acquire all of the shares of common stock of the Issuer, par value $0.0001 (the "Shares"), issued and outstanding immediately prior to the effective time of the merger (the "Effective Time"), in exchange for $48.00 in cash per Share, subject to any applicable withholding of taxes (the "Merger Consideration"). F2 · price: Pursuant to the terms of the Merger Agreement, each Share was tendered in exchange for $48.00 in cash per Share. Read SEC document |
| June 04, 2025 Filed Jun 6, 2025 16:38 UTC | Tourmaline Bio, Inc. TRML · Entity 15643 | GrantStock Option (Right to Buy) · Derivative | 16,800 | $0.00 Strike: $18.73 | $0.00 |
DisclosureSEC source: 0001827506-25-000082 · wk-form4_1749242295.xml · derivative · entry 1 Thiara Parvinder · CIK 0001995535 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,800 Underlying: Common Stock · 16,800 shares Expires 2035-06-04 F1 · derivative.exercise_date: 100% of the shares subject to the option vest on the earlier of the anniversary of the Transaction Date or the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| December 09, 2024 Filed Dec 11, 2024 21:45 UTC | Zura Bio Ltd ZURA · Entity 5413 | GrantShare Option (Right to Buy) · Derivative | 117,000 | $0.00 Strike: $2.76 | $0.00 |
DisclosureSEC source: 0001415889-24-028973 · form4-12112024_041205.xml · derivative · entry 1 Thiara Parvinder · CIK 0001995535 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,000 Underlying: Class A Ordinary Shares · 117,000 shares Expires 2034-12-09 F1 · derivative.exercise_date: This option vests in twelve substantially equal monthly installments over a one-year period measured from October 23, 2024; provided, that any remaining unvested portion of the option award will vest as of the day immediately preceding the next annual meeting of shareholders following the grant date, subject to the Reporting Person's continued service as of each such vesting date. Read SEC document |
| November 25, 2024 Filed Nov 27, 2024 21:15 UTC | Zura Bio Ltd ZURA · Entity 5413 | SaleClass A Ordinary Shares | 1,001,633 | $2.73 | $2,734,458.09 |
DisclosureSEC source: 0001415889-24-027847 · form4-11272024_041107.xml · nonDerivative · entry 1 Thiara Parvinder · CIK 0001995535 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 0 F1 · kind: The shares were disposed of by way of a private transaction. F2 · ownership.nature: Athanor Master Fund, LP (the "Master Fund") and Athanor International Master Fund, LP (the "International Master Fund", and together with the Master Fund, the "Funds") are the direct holders of the securities reported herein. Athanor Capital Partners, LP ("Master GP") is the general partner of the Master Fund. Athanor Capital Partners GP, LLC ("ACP GP") is the general partner of Master GP. Athanor International Fund GP, LP ("International Master GP") is the general partner of the International Master Fund. Athanor International Fund Ultimate GP, LLC ("AIFU GP") is the general partner of International Master GP. Athanor Capital, LP ("Athanor Capital") is the investment adviser to the Funds. Athanor Capital GP, LLC ("Athanor Capital GP") is the general partner of Athanor Capital. Parvinder Thiara is the managing member of Athanor Capital GP, AIFU GP and ACP GP. F3 · ownership.nature: By virtue of the foregoing relationships, Mr. Thiara and each of the entities named in footnote 2 above may be deemed to beneficially own the securities held by the Funds, however each of them disclaims beneficial ownership of such securities, except to the extent of his or its pecuniary interest therein. Read SEC document |
| September 11, 2024 Filed Sep 13, 2024 20:15 UTC | Zura Bio Ltd ZURA · Entity 5413 | SaleClass A Ordinary Shares | 3,800,000 | $2.70 | $10,260,000.00 |
DisclosureSEC source: 0001415889-24-023366 · form4-09132024_040916.xml · nonDerivative · entry 1 Thiara Parvinder · CIK 0001995535 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 1,001,633 F1 · kind: The shares were disposed of by way of a private transaction dated September 11, 2024. F2 · ownership.nature: Athanor Master Fund, LP (the "Master Fund") and Athanor International Master Fund, LP (the "International Master Fund", and together with the Master Fund, the "Funds") are the direct holders of the securities reported herein. Athanor Capital Partners, LP ("Master GP") is the general partner of the Master Fund. Athanor Capital Partners GP, LLC ("ACP GP") is the general partner of Master GP. Athanor International Fund GP, LP ("International Master GP") is the general partner of the International Master Fund. Athanor International Fund Ultimate GP, LLC ("AIFU GP") is the general partner of International Master GP. Athanor Capital, LP ("Athanor Capital") is the investment adviser to the Funds. Athanor Capital GP, LLC ("Athanor Capital GP") is the general partner of Athanor Capital. Parvinder Thiara is the managing member of Athanor Capital GP, AIFU GP and ACP GP. F3 · ownership.nature: By virtue of the foregoing relationships, Mr. Thiara and each of the entities named in footnote 2 above may be deemed to beneficially own the securities held by the Funds, however each of them disclaims beneficial ownership of such securities, except to the extent of his or its pecuniary interest therein. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 16:02 UTC | Tourmaline Bio, Inc. TRML · Entity 15643 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $13.91 | $0.00 |
DisclosureSEC source: 0001827506-24-000052 · wk-form4_1717790542.xml · derivative · entry 1 Thiara Parvinder · CIK 0001995535 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2034-06-04 F1 · derivative.exercise_date: 100% of the shares subject to the option vest on the earlier of the anniversary of the Transaction Date or the date of the Issuer's 2025 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| January 24, 2024 Filed Jan 26, 2024 16:30 UTC | Zura Bio Ltd ZURA · Entity 5413 | GrantStock options · Derivative | 48,149 | $0.00 Strike: $3.98 | $0.00 |
DisclosureSEC source: 0001104659-24-007064 · tm244212-2_4seq1.xml · derivative · entry 1 Thiara Parvinder · CIK 0001995535 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,149 Underlying: Class A Ordinary Shares · 48,149 shares Expires 2034-01-24 F1 · shares: Consists of options to purchase 48,149 Class A Ordinary Shares. The vesting for 48,149 shares began on June 22, 2023 and would vest over a period of three years, with each 1/3 on an annual basis. F1 · derivative.exercise_date: Consists of options to purchase 48,149 Class A Ordinary Shares. The vesting for 48,149 shares began on June 22, 2023 and would vest over a period of three years, with each 1/3 on an annual basis. Read SEC document |
| December 12, 2023 Filed Dec 14, 2023 20:35 UTC | Zura Bio Ltd ZURA · Entity 5413 | SaleClass A Ordinary Shares | 2,000,000 | $4.00 | $8,000,000.00 |
DisclosureSEC source: 0001104659-23-126005 · tm2332936-1_4seq1.xml · nonDerivative · entry 1 Thiara Parvinder · CIK 0001995535 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 4,801,633 F1 · ownership.nature: Athanor Master Fund, LP (the "Master Fund") and Athanor International Master Fund, LP (the "International Master Fund", and together with the Master Fund, the "Funds") are the direct holders of the securities reported herein. Athanor Capital Partners, LP ("Master GP") is the general partner of the Master Fund. Athanor Capital Partners GP, LLC is the general partner of Master GP. Athanor International Fund GP, LP ("International Master GP") is the general partner of the International Master Fund. Athanor International Fund Ultimate GP, LLC is the general partner of International Master GP. Athanor Capital, LP ("Athanor Capital") is the investment adviser to the Funds. Athanor Capital GP, LLC is the general partner of Athanor Capital. Parvinder Thiara is the managing member of Athanor Capital Partners GP, LLC, Athanor International Fund Ultimate GP, LLC and Athanor Capital GP, LLC. F2 · ownership.nature: By virtue of the foregoing relationships, Mr. Thiara and each of the entities named in this footnote may be deemed to beneficially own the securities held by the Funds, however each of them disclaims beneficial ownership of such securities, except to the extent of his or its pecuniary interest therein. Read SEC document |
| November 17, 2023 Filed Nov 20, 2023 18:14 UTC | Tourmaline Bio, Inc. TRML · Entity 15643 | PurchaseCommon Stock | 1,000 | $17.31 | $17,310.00 |
DisclosureSEC source: 0001209191-23-056126 · doc4.xml · nonDerivative · entry 1 Thiara Parvinder · CIK 0001995535 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,782 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $17.13 to $17.39 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| October 25, 2023 Filed Oct 26, 2023 16:46 UTC | Tourmaline Bio, Inc. TRML · Entity 15643 | PurchaseCommon Stock | 2,000 | $12.12 | $24,240.00 |
DisclosureSEC source: 0001209191-23-053670 · doc4.xml · nonDerivative · entry 2 Thiara Parvinder · CIK 0001995535 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,782 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.95 to $12.28 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| October 24, 2023 Filed Oct 26, 2023 16:46 UTC | Tourmaline Bio, Inc. TRML · Entity 15643 | PurchaseCommon Stock | 5,000 | $10.66 | $53,300.00 |
DisclosureSEC source: 0001209191-23-053670 · doc4.xml · nonDerivative · entry 1 Thiara Parvinder · CIK 0001995535 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,782 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.13 to $10.86 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| October 23, 2023 Filed Oct 23, 2023 20:33 UTC | Tourmaline Bio, Inc. TRML · Entity 15643 | GrantStock Option (Right to Buy · Derivative | 10,000 | $0.00 Strike: $9.46 | $0.00 |
DisclosureSEC source: 0001209191-23-053409 · doc4.xml · derivative · entry 2 Thiara Parvinder · CIK 0001995535 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2033-10-22 F3 · derivative.exercise_date: 100% of the shares subject to the option vest on the earlier of October 23, 2024 or the date of the Issuer's 2024 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| October 19, 2023 Filed Oct 23, 2023 20:33 UTC | Tourmaline Bio, Inc. TRML · Entity 15643 | GrantCommon Stock | 75,782 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-053409 · doc4.xml · nonDerivative · entry 1 Thiara Parvinder · CIK 0001995535 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,782 F1 · shares: 39,996 of these shares are subject to a repurchase option in favor of the Issuer in the event that the Reporting Person's continuous service is terminated. Such repurchase option shall lapse in equal monthly installments until such shares are fully vested on May 6, 2025. F2 · price: Received in exchange for 950,000 shares of common stock of Tourmaline Bio, Inc. ("Tourmaline") pursuant to an Agreement and Plan of Merger dated as of June 22, 2023 (the "Merger Agreement") by and among Tourmaline, the Issuer and Terrain Merger Sub, Inc., a wholly owned subsidiary of the Issuer ("Merger Sub"). Under the terms of the Merger Agreement, on October 19, 2023, Merger Sub merged with and into Tourmaline (the "Merger"), with Tourmaline surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, each share of Tourmaline common stock was converted into the right to receive 0.07977 of a share of the Issuer's common stock, after giving effect to a reverse stock split of the Issuer's common stock of 10-for-1. Subsequent to the Merger, the name of the Issuer was changed from Talaris Therapeutics, Inc. to Tourmaline Bio, Inc. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.